Literature DB >> 18816254

Treatment of IgA nephropathy of adults presented by nephrotic syndrome.

Senija Rasić1, Snjezana Uncanin, Kenana Aganović, Ismar Rasić, Jasminka Dzemidzić, Alma Muslimović.   

Abstract

The aim of this retrospective study was to evaluate the results of the immunosuppressive regiment in managing of IgA nephropathy associated with primary nephrotic syndrome at the Nephrology Clinic, University of Sarajevo Clinics Centre in period of 1997-2007. We studied 19 patients (4 women and 15 men) with idiopathic nephrotic syndrome, where pathomorphologic changes of IgA nephropathy were proved by kidney biopsy. The levels of diuresis, proteinuria, albuminemia, lipidemia and kidney function, as measure of efficiency of used therapy, were monitored. The IgA nephropathy present with the nephrotic syndrome was shown in 15.8% (19) patients underwent renal biopsy due to primary nephrotic syndrome in the period of observation. The average age of patients with IgA nephropathy was 34.9+/-14.1 years. Eight patients from this group were treated with corticosteroid therapy (1-1.5 mg/kg of body weight for 4 weeks, followed by 0.5 mg/ kg of body weight until therapeutic response was achieved, and finally gradual exclusion of therapy after eight weeks in responsive patients), 6 patients with corticosteroids and bolus cyclophosphamide (10-15 mg/kg BW), and in 5/19 patients cyclosporine therapy was used (3 mg/kg BW). Complete remission of nephrotic syndrome was achieved in 42.1% of the patients. In conclusion, in adults patients with primary nephrotic syndrome associated with IgA nephropathy, used immunosuppressive therapy resulted in a high percentage of achieved remissions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18816254      PMCID: PMC5694673          DOI: 10.17305/bjbms.2008.2923

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  13 in total

1.  The prognosis of IgA nephropathy--favorable or poor?

Authors:  S Nishi
Journal:  Intern Med       Date:  2001-08       Impact factor: 1.271

2.  Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.

Authors:  Francis W Ballardie; Ian S D Roberts
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

3.  Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases.

Authors:  M Haas
Journal:  Am J Kidney Dis       Date:  1997-06       Impact factor: 8.860

Review 4.  A retrospective analysis of the natural history of primary IgA nephropathy worldwide.

Authors:  F P Schena
Journal:  Am J Med       Date:  1990-08       Impact factor: 4.965

Review 5.  What is new in therapy of glomerulonephritis in 2003/2004.

Authors:  Z Hruby
Journal:  Rocz Akad Med Bialymst       Date:  2004

6.  IgA nephropathy histologically resembling focal-segmental glomerulosclerosis: a clinicopathologic study of 18 cases.

Authors:  M Haas
Journal:  Am J Kidney Dis       Date:  1996-09       Impact factor: 8.860

7.  Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy.

Authors:  Ritsuko Katafuchi; Kiyoshi Ikeda; Tohru Mizumasa; Hiroshi Tanaka; Takashi Ando; Tetsuro Yanase; Kohsuke Masutani; Michiaki Kubo; Satoru Fujimi
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

Review 8.  New perspectives in treatment of glomerulonephritis.

Authors:  Rosanna Coppo; Alessandro Amore
Journal:  Pediatr Nephrol       Date:  2003-12-13       Impact factor: 3.714

9.  IgA nephropathy: morphologic predictors of progressive renal disease.

Authors:  S M Lee; V M Rao; W A Franklin; M S Schiffer; A J Aronson; B H Spargo; A I Katz
Journal:  Hum Pathol       Date:  1982-04       Impact factor: 3.466

10.  Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.

Authors:  Claudio Pozzi; Simeone Andrulli; Lucia Del Vecchio; Patrizia Melis; Giovanni B Fogazzi; Paolo Altieri; Claudio Ponticelli; Francesco Locatelli
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

View more
  3 in total

1.  Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.

Authors:  Feng Ma; Xiaoxia Yang; Meilan Zhou; Ming Bai; Lijuan Zhao; Li Li; Ruijuan Dong; Chunmei Liu; Rong Li; Shiren Sun
Journal:  J Nephrol       Date:  2020-05-23       Impact factor: 3.902

2.  Severity of nephrotic IgA nephropathy according to the Oxford classification.

Authors:  Takahito Moriyama; Kayu Nakayama; Chihiro Iwasaki; Ayami Ochi; Yuki Tsuruta; Mitsuyo Itabashi; Misao Tsukada; Takashi Takei; Keiko Uchida; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2012-01-10       Impact factor: 2.370

3.  Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.

Authors:  Zhijuan Kang; Zhihui Li; Cuirong Duan; Tianhui Wu; Mai Xun; Yunfeng Ding; Yi Zhang; Liang Zhang; Yan Yin
Journal:  Pediatr Nephrol       Date:  2015-03-15       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.